Active Not Recruiting NA INTERVENTIONAL 2-arm NCT05912231

Ultrahypofractionation and Normal Tissue Toxicity

Proton Versus Photon Ultrahypofractionated Radiation Therapy and Its Impact on Normal Tissue

Sponsor: American Society of Clinical Oncology

Conditions Breast Cancer Breast Cancer Female Breast Cancer Stage II Breast Cancer Stage III Myocardial Fibrosis

Interventions Accelerated Photon Radiation Therapy (XRT) Accelerated Proton Beam Radiation Therapy (PBT)

Updated 6 times since 2023 Last updated: Nov 12, 2025 Started: Aug 15, 2023 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05912231, this NA trial focuses on Breast Cancer and Breast Cancer Female and remains ongoing. Sponsored by American Society of Clinical Oncology, it has been updated 6 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Dec 2025 — Present [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting
Sep 2024 — Dec 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Feb 2024 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Nov 2023 — Feb 2024 [monthly]

Not Yet Recruiting NA

▶ Show 1 earlier version

Jul 2023 — Nov 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Society of Clinical Oncology
Massachusetts General Hospital
National Cancer Institute (NCI)

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States